权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

EPLIN as a Molecular Target of Genistein in Preventing Prostate Cancer Metastasis

EPLIN 作为金雀异黄素预防前列腺癌转移的分子靶点

基本信息

批准号：
8386046
负责人：
DAQING WU
金额：
$ 20.34万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-07-09 至 2014-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8386046
关键词：
Actins Adherens Junction Animal Model Biological Markers Cancer Model Cancer Patient Cause of Death Cells Chronic Disease Clinical Clinical Trials Colorectal Cancer Consumption Country Cytoskeleton Development Diet Disease Down-Regulation Epithelial Experimental Models Family Gene Targeting Genetic Transcription Genistein Head and Neck Squamous Cell Carcinoma Healthcare Healthcare Systems Human In Vitro Incidence Isoflavones Malignant Neoplasms Malignant neoplasm of prostate Mediating Medical Metastatic Prostate Cancer Modeling Molecular Molecular Target Neoplasm Metastasis Neoplasms Oncogenes Patients Pharmaceutical Preparations Phenotype Pre-Clinical Model Prevention Preventive Printing Prostate Proteins PubMed Regulation Reporting Repression Risk Role Signal Transduction Snails Solid Neoplasm Staging Surrogate Endpoint Testing Tumor Suppressor Proteins United States Xenograft Model base cancer cell cost cost effective epithelial to mesenchymal transition improved in vivo inhibitor/antagonist link protein lymph nodes malignant breast neoplasm men mortality novel pre-clinical prevent promoter soy survivorship tumor

项目摘要

DESCRIPTION (provided by applicant): EPLIN as a Molecular Target of Genistein In Preventing Prostate Cancer Metastasis Genistein, a major dietary isoflavone whose consumption is associated with reduced mortality in prostate cancer (PCa) patients, has emerged as a promising inhibitor of metastasis. Nonetheless, the mechanism of action of genistein in blocking metastatic cascade in cancer cells remains largely unknown. In this application, we will test the hypothesis that the induction of EPLIN is a crucial mechanism wherein genistein inhibits the acquisition of invasiveness by PCa cells and prevents tumor metastasis. We proposed two Specific Aims. In Aim 1, we will elucidate the molecular mechanism by which genistein upregulates EPLIN and inhibits EMT in PCa cells. The hypothesis is that genistein induces EPLIN expression at transcriptional level, thereby inhibiting EMT and suppressing invasive phenotypes. We will determine whether genistein activates EPLIN promoter by inhibiting Snail-dependent repression of EPLIN promoter. The in vitro effects of genistein on the invasiveness of PCa cells will be examined. This Aim will elucidate a novel mechanism of action of genistein in blocking the metastatic cascade in PCa cells. In Aim 2, we will determine the in vivo effects of genistein in upregulating EPLIN and preventing metastasis in pre-clinical models. The hypothesis is that in vivo administration of genistein could effectively increase EPLIN expression and significantly reduce metastatic incidence in animal models. An intracardiac model for PCa metastasis will be used to evaluate the in vivo efficacy of genistein in upregulating EPLIN, inhibiting EMT and reducing metastatic incidence. These studies will provide mechanistic basis and novel biomarkers for clinical investigation of genistein in the prevention of metastasis at early stages, therefore significantly contributing to our efforts of improving survivorship in PCa patients. PUBLIC HEALTH RELEVANCE: EPLIN as a Molecular Target of Genistein In Preventing Prostate Cancer Metastasis Metastasis is the major cause of death from prostate cancer, the most common cancer in men in Western countries. Although several new drugs are currently available for the management of metastatic disease, these therapies can only extend the median survival by approximately 3 months at high cost, which poses a huge burden on patients, their families and the healthcare system. Given the promise of genistein as a safe, efficacious and cost-effective preventive agent that could be implemented before the development of metastasis, it is imperative to understand the molecular mechanism by which genistein inhibits prostate cancer metastasis. Our application will provide mechanistic basis and novel biomarkers for clinical investigation of genistein in the prevention of metastasis at early stages, which could significantly contribute to our efforts of reducing cancer mortality and improving healthcare in the United States and globally.

描述（由申请人提供）：EPLIN 作为金雀异黄酮的分子靶标预防前列腺癌转移金雀异黄酮是一种主要的膳食异黄酮，其摄入量与降低前列腺癌 (PCa) 患者的死亡率相关，已成为一种有前景的转移抑制剂。尽管如此，金雀异黄素阻断癌细胞转移级联的作用机制仍然很大程度上未知。在本申请中，我们将测试以下假设：EPLIN 的诱导是金雀异黄素抑制 PCa 细胞获得侵袭性并防止肿瘤转移的关键机制。我们提出了两个具体目标。在目标 1 中，我们将阐明金雀异黄素上调 EPLIN 并抑制 PCa 细胞 EMT 的分子机制。假设金雀异黄素在转录水平诱导 EPLIN 表达，从而抑制 EMT 并抑制侵袭表型。我们将确定金雀异黄素是否通过抑制 EPLIN 启动子的 Snail 依赖性抑制来激活 EPLIN 启动子。将检查金雀异黄素对 PCa 细胞侵袭力的体外影响。该目标将阐明金雀异黄素阻断 PCa 细胞转移级联的新作用机制。在目标 2 中，我们将确定金雀异黄素在临床前模型中上调 EPLIN 和预防转移的体内作用。假设在动物模型中体内施用金雀异黄素可以有效增加 EPLIN 表达并显着降低转移发生率。 PCa 转移的心内模型将用于评估金雀异黄素在治疗中的体内功效。上调 EPLIN，抑制 EMT 并降低转移发生率。这些研究将为金雀异黄素预防早期转移的临床研究提供机制基础和新的生物标志物，从而为我们提高前列腺癌患者的生存率做出重大贡献。公共健康相关性：EPLIN 作为金雀异黄素的分子靶标预防前列腺癌转移前列腺癌是西方国家男性最常见的癌症，转移是导致死亡的主要原因。尽管目前已有多种新药可用于治疗转移性疾病，但这些疗法只能将中位生存期延长约3个月，而且成本高昂，这给患者、其家人和医疗保健系统带来了巨大负担。鉴于金雀异黄素有望成为一种安全、有效且具有成本效益的预防剂，可以在发生转移之前使用，因此有必要了解金雀异黄素抑制前列腺癌转移的分子机制。我们的应用将为金雀异黄素预防早期转移的临床研究提供机制基础和新型生物标志物，这可以为我们降低癌症死亡率和改善美国和全球医疗保健的努力做出重大贡献。